Skip to main content
Clinical Trials/NCT05759065
NCT05759065RecruitingNot Applicable

A Hybrid Effectiveness Implementation Trial Evaluating Behavioral Treatments for Insomnia for Socioeconomically Disadvantaged Adults in Primary Care

Brigham and Women's Hospital1 site in 1 country350 target enrollmentStarted: April 2, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
350
Locations
1
Primary Endpoint
Insomnia severity index, ISI

Study Overview

Brief Summary

The overall objective of this study is to conduct a randomized effectiveness-implementation trial to test the non-inferiority of tele-Brief Behavioral Treatment for Insomnia vs. tele-Cognitive-Behavioral Therapy for Insomnia among socioeconomically disadvantaged adults with insomnia in the primary care setting.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Aged 18 years or older
  • Meet clinical diagnostic criteria for insomnia (DSM-V criteria)
  • Insomnia severity score > 10
  • Eligible to receive care through publicly-supported medical assistance (e.g. Commonwealth Connector plan; MassHealth. For participants >65 years old on Medicare, they will be asked about insurance coverage prior to initiating Medicare, OR
  • Identify as racial or ethnic minority
  • Has capacity for informed consent (SDT<9)

Exclusion Criteria

  • Untreated, current major depressive disorder (PHQ-8≥ 20)
  • History of bipolar disorder or psychosis
  • Active alcohol abuse (Alcohol Use Disorders Identification Test, AUDIT-C) or drug abuse (Drug Abuse Screening Test, DAST-2 ≥1)
  • Excessive daytime sleepiness (Epworth Sleepiness Scale score ≥ 16)
  • Seizure within the past 1 year
  • Main sleep period outside of 8pm - 11am
  • Regular nightshift work (5 overnight shifts/month, defined as working between midnight-5am)
  • Untreated, previously diagnosed moderate to severe sleep apnea
  • Severe medical condition, which may require hospitalizations over the next 6 months
  • Active suicidal ideation, if elicited passively during screening
  • Pregnant or planning to become pregnant (self-reported)
  • Participation in other studies that may impact the benefit or safety of the intervention, as determined by the study PI

Arms & Interventions

Tele-Brief Behavioral Treatment for Insomnia

Experimental

Intervention: Tele-Brief Behavioral Treatment for Insomnia (Behavioral)

Tele-Cognitive-Behavioral Therapy for Insomnia

Active Comparator

Intervention: Tele-Cognitive-Behavioral Therapy for Insomnia (Behavioral)

Outcomes

Primary Outcomes

Insomnia severity index, ISI

Time Frame: 3 months

The Insomnia Severity Index is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia in the last month. A 5-point Likert scale is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).

Secondary Outcomes

  • Diary reported sleep duration(3-months)
  • Quality of Life and Symptoms - Generic-quality of life(3-months)
  • Generalized Anxiety Disorder (GAD-7)(3-months)
  • Number of participants with hypnotic use self-reported from the sleep diary(3-months)
  • Quality of Life and Symptoms - Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health(3-months)
  • Patient Health Questionnaire for depression (PHQ-8)(3-months)
  • Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Impairment, 8a(3-months)
  • Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance, 8b(3-months)
  • Diary-reported sleep efficiency(3-months)
  • Insomnia severity index, ISI(6- and 12-months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Suzanne M. Bertisch, MD, MPH

Associate Physician, Clinical Director of Behavioral Sleep Medicine

Brigham and Women's Hospital

Study Sites (1)

Loading locations...

Similar Trials